Lung cancer Posts on Medivizor
Navigation Menu

Lung cancer Posts on Medivizor

Evaluating the effectiveness and safety of different platinum-based chemotherapy regimens given after surgery for the treatment of early-stage resected NSCLC.

Evaluating the effectiveness and safety of different platinum-based chemotherapy regimens given after surgery for the treatment of early-stage resected NSCLC.

Posted by on Jan 3, 2023 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of different platinum-based chemotherapy regimens given after surgery for the treatment of early-stage resected non-small cell lung cancer (NSCLC). The authors concluded that the combination of cisplatin (Platinol)-vinorelbine (Nevelbine) improved the outcomes of these patients. Also, the...

Read More

Evaluating the effectiveness and safety of anlotinib as a third-line treatment in patients with advanced NSCLC.

Evaluating the effectiveness and safety of anlotinib as a third-line treatment in patients with advanced NSCLC.

Posted by on Dec 31, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of anlotinib (AL3818) as a third-line treatment in patients with advanced non-small cell lung cancer (NSCLC). The data showed that anlotinib as a third-line treatment was effective with manageable side effects in these patients. Some background NSCLC is the most common form of lung...

Read More

Evaluating the effectiveness and safety of ramucirumab and pembrolizumab versus standard of care in previously treated patients with advanced NSCLC.

Evaluating the effectiveness and safety of ramucirumab and pembrolizumab versus standard of care in previously treated patients with advanced NSCLC.

Posted by on Dec 9, 2022 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety outcomes of ramucirumab (Cyramza) and pembrolizumab (Keytruda) versus standard of care (SOC) in previously treated patients with advanced non-small cell lung cancer (NSCLC). The data showed that ramucirumab and pembrolizumab significantly improved overall survival compared with SOC in...

Read More

Comparing the effectiveness and safety of PD-1/PD-L1 inhibitors versus chemotherapy for the treatment of patients with non-small-cell lung cancer.

Comparing the effectiveness and safety of PD-1/PD-L1 inhibitors versus chemotherapy for the treatment of patients with non-small-cell lung cancer.

Posted by on Dec 4, 2022 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness and safety outcomes of different programmed death-1 (PD-1)/PD ligand 1 (PD-L1) inhibitors versus chemotherapy for the treatment of patients with non-small-cell lung cancer (NSCLC). The data showed that PD-1/PD-L1 inhibitors were safer and more effective than chemotherapy with cemiplimab (Libtayo)...

Read More

Evaluating the effectiveness and safety of tiragolumab plus atezolizumab as a first-line treatment for patients with non-small cell lung cancer.

Evaluating the effectiveness and safety of tiragolumab plus atezolizumab as a first-line treatment for patients with non-small cell lung cancer.

Posted by on Nov 22, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of atezolizumab (Tecentriq) alone or with tiragolumab (MTIG7192A) as a first-line treatment for patients with non-small cell lung cancer (NSCLC). The data showed that tiragolumab plus atezolizumab significantly improved the objective response rate and the survival without...

Read More

Evaluating the effectiveness and safety of adebrelimab plus standard chemotherapy as first-line treatment for extensive-stage small cell lung cancer.

Evaluating the effectiveness and safety of adebrelimab plus standard chemotherapy as first-line treatment for extensive-stage small cell lung cancer.

Posted by on Oct 16, 2022 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety outcomes of adebrelimab (SHR-1316) plus carboplatin (Paraplatin) and etoposide (Etopophos)-based chemotherapy as first-line treatment for extensive-stage (ES) small-cell lung cancer (SCLC). The data showed that adebrelimab added to standard chemotherapy as first-line treatment...

Read More

Comparing the effectiveness and safety of immune checkpoint inhibitors between randomized and real-world studies in patients with advanced NSCLC or melanoma.

Comparing the effectiveness and safety of immune checkpoint inhibitors between randomized and real-world studies in patients with advanced NSCLC or melanoma.

Posted by on Oct 7, 2022 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of immune checkpoint inhibitors (ICIs) between randomized and real-world studies in patients with advanced non-small cell lung cancer (NSCLC) or melanoma. The data showed that ICIs were similarly effective and safe in both randomized and real-world studies for these patients. Some background...

Read More

Evaluating the effectiveness of first-line treatments in the elderly and non-elderly patients with advanced EGFR-mutated NSCLC.

Evaluating the effectiveness of first-line treatments in the elderly and non-elderly patients with advanced EGFR-mutated NSCLC.

Posted by on Oct 7, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness of different first-line treatments in elderly and non-elderly patients with advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). The data showed that osimertinib (Tagrisso) was the best treatment regimen to improve survival without cancer worsening in elderly...

Read More

Evaluating treatment outcomes of fractionated stereotactic radiotherapy in patients with small and moderate-sized brain metastases.

Evaluating treatment outcomes of fractionated stereotactic radiotherapy in patients with small and moderate-sized brain metastases.

Posted by on Sep 17, 2022 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of fractionated stereotactic radiation therapy (FSRT) for patients with small and moderate-sized brain metastases (BM). The data showed that FSRT was safe and effective in patients with BM of any size with excellent local control. Some background Stereotactic radiosurgery (SRS) is...

Read More

Air Pollution Links to Lung Cancer

Air Pollution Links to Lung Cancer

Posted by on Sep 15, 2022 in Blog, Lung cancer | 0 comments

While smoking remains the primary cause of lung cancer, 10 – 20% of people who develop non-small cell lung cancer (NSCLC) never smoked. NSCLC in non-smokers happens more often to women, and at an earlier age, than it does in smokers.  What would cause cancer to develop without smoking? [1] One theory is that environmental factors,...

Read More

Evaluating the impact of immunetherapy on COVID-19 outcomes in patients with cancer.

Evaluating the impact of immunetherapy on COVID-19 outcomes in patients with cancer.

Posted by on Sep 1, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic. Some...

Read More

Evaluating the effectiveness and safety of sugemalimab after chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer.

Evaluating the effectiveness and safety of sugemalimab after chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer.

Posted by on Sep 1, 2022 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of sugemalimab (Cejemly) after treatment with concurrent or sequential chemoradiotherapy (CRT) in patients with unresectable stage III non-small cell lung cancer (NSCLC). The data showed that sugemalimab significantly increased the survival without cancer worsening with manageable...

Read More